Evidence map›Paper›PMID 41190279›Full record

ReviewMedComm2025

Human Endogenous Retroviruses and Diseases.

Can Chen, Yanru Cui, Shixiang Wang, Yuze Yang, Zunpeng Liu, Suhan Jin, Fangqian Shen, Udo Gaipl, Hu Ma, Jian-Guo Zhou

Abstract readReview
In one paragraph

Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Evolution ofInternational journal of molecular sciences · 2026
    Review
  4. Article
  5. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Can ChenDepartment of Oncology The Second Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China.ORCID https://orcid.org/0009-0005-0501-7981
Yanru CuiMeinig School of Biomedical Engineering Cornell University Ithaca New York USA.
Shixiang WangDepartment of Biomedical Informatics School of Life Sciences Central South University Changsha China.
Yuze YangSchool of Medicine Tsinghua University Beijing China.
Zunpeng LiuComputer Science and Artificial Intelligence Lab Massachusetts Institute of Technology Cambridge Massachusetts USA.
Suhan JinDepartment of Orthodontics Affiliated Stomatological Hospital of Zunyi Medical University Zunyi China.
Fangqian ShenDepartment of Oncology The Second Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China.
Udo GaiplDepartment of Radiation Oncology Translational Radiobiology Universitätsklinikum Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg Erlangen Germany.
Hu MaDepartment of Oncology The Second Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China.
Jian-Guo ZhouDepartment of Oncology The Second Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China.ORCID https://orcid.org/0000-0002-5021-3739

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human endogenous retroviruses (HERVs), remnants of ancient retroviral infections, comprise nearly 8% of the human genome and play dual roles in physiological regulation and disease pathogenesis. Once considered genomic "fossils," HERVs are now known to dynamically influence gene expression, immunity, and homeostasis via epigenetic regulation, molecular mimicry, and viral mimicry. Their structural components, including long terminal repeats and conserved viral genes, enable them to act as regulatory elements and potential sources of novel antigens. However, the causal mechanisms linking the dysregulation of HERVs to diseases-the technical challenges in their detection and quantification, as well as their therapeutic potential-remain poorly systematized. This review synthesizes the molecular architecture and evolutionary trajectories of HERVs, emphasizing their tissue-specific expression patterns. We further delineates their pathogenic roles in diseases including cancer, autoimmune conditions, and neurodegenerative disorders. Finally, we discuss emerging strategies targeting HERVs, including epigenetic modulators, immunotherapies, and gene editing, alongside ongoing clinical trials and translational challenges. By integrating molecular insights with clinical perspectives, this work provides a foundational framework for leveraging HERVs as biomarkers and therapeutic targets in precision medicine.

Indexed as

human endogenous retroviruses; genetic domestication; transcriptional regulation; molecular mimicry; therapeutic targets

Identifiers

PMID41190279
PMCPMC12580410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.